Tingting Lu

Publications (2)8.51 Total impact

• Article: Soluble C-X-C chemokine ligand 16 levels are increased in gout patients.

  Qi Gong, Fan Wu, Xuebo Pan, Jiawen Yu, Yilan Li, Tingting Lu, Xiaokun Li, Zhuofeng Lin
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVES: Soluble C-X-C chemokine ligand 16 (CXCL16) was shown to recruit polymorphonuclear cells into synovial tissue in gout patients. The aim of this study was to explore the pathophysiological characteristics of CXCL16 in gout patients with or without chronic kidney disease (CKD). DESIGN AND METHODS: 42 gout patients, 22 CKD and 20 healthy subjects were enrolled. Plasma CXCL16 and other biochemical parameters were tested. RESULTS: Plasma CXCL16 levels in gout subjects with CKD were significantly increased compared with healthy, CKD and gout subjects without CKD. Soluble CXCL16 levels in gout subjects were closely correlated with renal function and lipid profiles, and independently associated with 24h proteinuria, creatinine clearance rate and C-reactive protein. CONCLUSION: Our data indicated that plasma CXCL16 levels are significantly increased in gout patients with and without CKD, and are independently associated with renal function. Elucidating the pathophysiologcial role of CXCL16 in gout patients requires further study.
  Clinical biochemistry 05/2012; · 2.02 Impact Factor
• Article: Dynamic change of serum FGF21 levels in response to glucose challenge in human.

  Zhuofeng Lin, Qi Gong, Chaoming Wu, Jiawen Yu, Tingting Lu, Xuebo Pan, Shaoqiang Lin, Xiaokun Li
  [show abstract] [hide abstract]
  ABSTRACT: Fibroblast growth factor 21 (FGF21), an endocrine factor predominantly secreted from liver, possesses multiple beneficial effect on energy metabolism and insulin sensitivity in animals. This study aimed to investigate the acute change of serum FGF21 in response to glucose challenge in humans. A 75-g oral glucose tolerance test was performed among 20 healthy subjects, 18 with impaired glucose tolerance (IGT) and 21 with type 2 diabetes mellitus (T2DM). Blood samples were collected for measurement of FGF21 and other biochemical parameters. The associations of FGF21 with insulin and other metabolic parameters were analyzed. Fasting serum FGF21 levels increased progressively from healthy, IGT to T2DM subjects (P < 0.05 for global trend). After oral glucose administration, the serum FGF21 level showed a similar biphasic change in all three groups. It declined to a nadir level at 60 min and then increased gradually to its peak level at 180 min. FGF21 levels at different time points of oral glucose tolerance test negatively correlated with glucose levels in all subjects, and the fold change of serum FGF21 at different time points (compared with the basal level) were inversely associated with fold changes of insulin (P = 0.012) and C-peptide (P = 0.043) levels in healthy subjects but not in IGT and T2DM patients. The dynamic change of circulating FGF21 was associated with alterations in insulin levels in response to glucose challenge in humans. These findings support the role of FGF21 as a potential regulator of insulin secretion and glucose metabolism in humans.
  The Journal of clinical endocrinology and metabolism 04/2012; 97(7):E1224-8. · 6.50 Impact Factor